Epratuzumab is a monoclonal antibody that targets the CD22 antigen, primarily expressed on the surface of B cells. It is classified as an immunotherapeutic agent and is primarily investigated for its potential in treating autoimmune diseases and certain types of B-cell malignancies, such as non-Hodgkin lymphoma. Epratuzumab functions by modulating B-cell activity, leading to a reduction in autoantibody production and influencing the immune response. The molecular structure of Epratuzumab consists of humanized IgG1, which enhances its stability and reduces immunogenicity compared to murine antibodies. Its mechanism of action involves binding to CD22, which plays a critical role in B-cell signaling and regulation. Epratuzumab has undergone various clinical trials to assess its efficacy and safety profile, particularly in conditions like systemic lupus erythematosus and rheumatoid arthritis. As with many biologics, its administration is typically via subcutaneous or intravenous routes, and it may be associated with specific side effects related to immune modulation.

Epratuzumab

205923-57-5: Epratuzumab is a monoclonal antibody that targets the CD22 antigen, primarily expressed on the surface of B cells. It is classified as an immunotherapeutic agent and is primarily investigated for its potential in treating autoimmune diseases and certain types of B-cell malignancies, such as non-Hodgkin lymphoma. Epratuzumab functions by modulating B-cell activity, leading to a reduction in autoantibody production and influencing the immune response. The molecular structure of Epratuzumab consists of humanized IgG1, which enhances its stability and reduces immunogenicity compared to murine antibodies. Its mechanism of action involves binding to CD22, which plays a critical role in B-cell signaling and regulation. Epratuzumab has undergone various clinical trials to assess its efficacy and safety profile, particularly in conditions like systemic lupus erythematosus and rheumatoid arthritis. As with many biologics, its administration is typically via subcutaneous or intravenous routes, and it may be associated with specific side effects related to immune modulation.

<p>Epratuzumab (AMG 41) is a humanized monoclonal antibody targeting CD22, also a tumor imaging agent, inducing CD22 phosphorylation.</p>

<p>Anti-Human CD22 Recombinant Antibody</p>

CAS 205923-57-5

Epratuzumab

Epratuzumab

Ref: TM-T76805

Epratuzumab

Ref: 3D-CLA1063